Aadi Bioscience Past Earnings Performance
Past criteria checks 0/6
Aadi Bioscience's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 28% per year.
Key information
-27.1%
Earnings growth rate
12.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 28.0% |
| Return on equity | -62.5% |
| Net Margin | -270.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25Revenue & Expenses BreakdownBeta
How Aadi Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 24 | -66 | 45 | 0 |
| 30 Sep 23 | 23 | -63 | 45 | 0 |
| 30 Jun 23 | 22 | -62 | 44 | 9 |
| 31 Mar 23 | 19 | -62 | 42 | 0 |
| 31 Dec 22 | 15 | -61 | 40 | 0 |
| 30 Sep 22 | 11 | -63 | 39 | 0 |
| 30 Jun 22 | 7 | -136 | 36 | 13 |
| 31 Mar 22 | 3 | -119 | 27 | 0 |
| 31 Dec 21 | 1 | -111 | 19 | 0 |
| 30 Sep 21 | 14 | -87 | 9 | 0 |
| 30 Jun 21 | 15 | -2 | 2 | 0 |
| 31 Mar 21 | 15 | -6 | 2 | 0 |
| 31 Dec 20 | 15 | -4 | 2 | 0 |
| 31 Dec 19 | 1 | -13 | 2 | 0 |
Quality Earnings: AADI is currently unprofitable.
Growing Profit Margin: AADI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AADI is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare AADI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AADI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: AADI has a negative Return on Equity (-62.52%), as it is currently unprofitable.